Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $28.07 (market cap $72.36M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.69 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 349.2× KraneShares Electric Vehicles and Future Mobility's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while KraneShares Electric Vehicles and Future Mobility pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 46 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| KARS | RPRX | |
|---|---|---|
Market Cap | $72.36M | $25.27B |
Volume | 5,034 | 3,671,183 |
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $63.96 |
52-Week Low | $27.25 | $35.44 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
